The cytochrome P450 (CYP) enzymes are the major drug-metabolizing enzyme system in humans. Inter-individual variability affects the activity of these enzymes, and consequently drug clearance. Besides the metabolizing enzymes, another source of PK variability in drug response are the influx and efflux proteins, such as P-glycoprotein (P-gp). The PK variability and the modifications in CYP and/or transporter activities (such as P-gp) can cause various pharmacological and toxicological consequences. It is therefore important to precisely and reliably evaluate their in vivo activity (phenotyping). Phenotyping tests can be either individual (evaluating the activity of a single cytochrome or transporter) or simultaneous (assessing the activity of multiple enzymes/transporters). Simultaneous phenotyping is performed by the in vivo administration of a cocktail of probe drugs, each of which is metabolized by one specific cytochrome or transported by P-gp, followed by the determination of an appropriate PK parameter of the probe drug or a ratio between the drug and its metabolite (metabolic ratio) [1].
more patient-friendly [10] . Moreover, DBS sampling does not require the use of anticoagulant or plasma separation and can be easily stored and shipped to analytical laboratories without using refrigerated devices, which also makes it more cost effective in comparison with the conventional sampling methods [11] .
The DBS sampling method has been successfully applied for the determination of drug concentrations in numerous TK and PK studies [12] [13] [14] [15] [16] , as well as for therapeutic drug monitoring [17] [18] [19] [20] . Some studies have shown that DBS sampling could also be used for individual cytochrome phenotyping of either CYP2C9 [2, 21] or CYP3A [22] activities. The utility of DBS sampling for cytochrome activity assessment has been underlined in a recent study, where five individual analytical methods for the quantification of CYP probe substrates in DBS have been developed [23] .
This article describes the development, validation and application of a single method for the quantification of six CYP specific probe substrates (CAF, BUP, FLB, OPZ, DEM and MDZ) and their metabolites, as well as a P-gp substrate (FEX) in DBS and plasma.
Experimental
Chemicals & reagents CAF, paraxanthine (PAR), FLB, OPZ and FEX were purchased from Sigma-Aldrich (Buchs, Switzerland). DEM, dextrorphan (DOR), MDZ and 1-hydroxy-MDZ (OH-MDZ) were kindly donated by Hoffman-La-Roche (Basel, Switzerland). BUP, hydroxybupropion (OH-BUP) and MDZ-d4 were purchased from Cerilliant (TX, USA). 5-hydroxyOPZ (OH-OPZ), 4-hydroxy-FLB (OH-FLB), OPZ-d3 and FLB-d3 were purchased from Toronto Research Chemicals (ON, Canada). Both acetonitrile (ACN) and methanol (MeOH) were of HPLC grade from Merck (Darmstadt, Germany). Fresh human CAF and drug-free blood and plasma with EDTA as anticoagulant were supplied by Geneva University Hospitals (Geneva, Switzerland). Stock solutions of each analyte at a concentration of 1 mg/ml were prepared in MeOH, except for OH-BUP in ACN, and were stored at -20°C.
Working standard solutions were prepared by dilution of the stock solutions in MeOH to reach concentration of 5000 ng/ml for CAF, PAR and FLB; 1000 ng/ml for OH-FLB; 500 ng/ml for DOR; 200 ng/ml for BUP, OH-BUP, OPZ, OH-OPZ, DEM, OH-MDZ and FEX; and 100 ng/ml for MDZ.
Preparation of calibration standards & QC samples
Spiked blood and plasma needed for the calibrators and QCs were prepared using fresh EDTA whole blood or plasma, respectively. Appropriate volumes of the working standard solutions were evaporated in Eppendorf tubes and whole blood or plasma was then added into the tubes to reach the desired concentrations.
Plasma and DBS calibration standards and QCs were prepared using separate working solutions.
Sample pretreatment DBS
A 10 µl volume of real or spiked whole blood was spotted onto a filter paper 903 protein saver card from Whatman (MA, USA) using a volumetric (0.1-10 µl) micropipette (Rainin, CA, USA). The DBS collection cards were bent so that the back of the card was not in contact with any surface to prevent loss of blood that soaked through the filter paper. DBS samples were allowed to dry at room temperature for at least 1 h and were then packed in a sealable plastic bag containing desiccant until ana lysis (no later than 15 days postspotting). They were stored in the dark at ambient temperature, except for the clinical study samples (at -20°C), and stability experiments in which various storing temperatures were tested.
Discs of 6 mm diameter covering the entire DBS were punched out and folded into the bottom of individual LC vials containing a 300 µl inert insert. Using the whole spot in association with a previous volumetric control has the advantage of overcoming the impact that hematocrit can have on the spreading of the applied drop of blood. For the extraction, MeOH (100 µl) containing the IS (MDZ-d4 1 ng/ml, OPZ-d3 5 ng/ml and FLB-d3 50 ng/ml) was added to each vial. The vials were then sealed, vortex-mixed and positioned in the LC rack.
Plasma
Spiked or real plasma samples (50 µl) were put in an eppendorf tube to which 5 µl of ACN containing the IS (100 ng/ml of MDZ-d4, 500 ng/ml of OPZ-d3 and 5000 ng/ml of FLB-d3) was added. A protein precipitation (PP) was performed by adding 195 µl of ACN, followed by vortex-mixing. The samples were then centrifuged for 3 min at 10000 rpm. The supernatant (50 µl) was added to a LC vial and diluted with water (1:1).
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LC-MS/MS ana lysis
Blood (i.e., DBS or plasma) ana lysis was performed using a LC-MS/MS system consisting of a 5500QTrap ® triple quadrupole linear ion trap (QqQ LIT ) mass spectrometer equipped with a TurboIon Spray TM interface (AB Sciex, ON, Canada) and an Ultimate 3000 RS instrument (Dionex, CA, USA) as LC system. Data were acquired and processed using Analyst software (version 1.5.2; AB Sciex, Toronto, Canada).
Before injection, the autosampler needle was filled with 50 µl of water by means of the user defined program function. Then, 5 µl of DBS or plasma extract was injected into the LC-MS/MS system. To avoid any contact with DBS samples folded into the vial, the needle height was set at 6 mm.
The chromatographic separation was conducted on a 50 mm length × 2.1 mm internal diameter, 2.6 µm particle size, Kinetex™ RP C18 XB column (Phenomenex, CA, USA). The mobile phase consisted of a mixture of H 2 O and ACN set at a flow rate of 0.6 ml/min. A linear gradient was employed from H 2 O/ACN (98/2, v/v) to H 2 O/ACN (2/98, v/v) over 2 min. These proportions were maintained for 1 min before re-equilbrating the column with the initial c onditions. The method featured a 6 min total run-time per ana lysis.
The MS TurboIonSpray interface was operated in dual ionization mode with continuous polarity switching. The capillary potential was of +4500 and -4000 V for the positive and negative ESI modes, respectively. Nitrogen was used as the curtain and nebulizer gas, and the source parameters were set to a temperature of 650°C, an entrance potential of 10 V, a collision cell exit potential of 10 V, a curtain gas pressure of 20 psi, a nebulizer gas (GS1) pressure of 30 psi and an auxiliary gas (GS2) pressure of 40 psi.
The MS detection was operated in SRM mode based on colli sion-induced dissociation occurring in the colli sion cell (quadrupole two). The dwell-time was set to 4 ms. All other settings were analyte-specific and were determined using Analyst software in compound optimization mode. Quantification transitions with parameters are listed in Table 1 .
Method validation
The method was fully validated according to the guidelines of the European Medicines Agency [102] .
For each of the 3 nonconsecutive days, calibration standards were prepared in duplicate (n = 2) at seven concentration levels for CAF, PAR, BUP, OH-BUP, FLB, OH-FLB and fexofenadine, at eight concentration levels for OPZ and OH-OPZ, and at nine concentration levels for DEM, DOR, MDZ and OH-MDZ, which have the largest calibration range (Table 1) . QC samples were prepared in whole blood or plasma in quadruplicate (n = 4) at four concentration levels representing Tables 2 & 3 . The validation process allowed the determination of specific criteria such as accuracy, precision, li nearity, LLOQ and LOD. The linearity of the method was evaluated by back-calculating QC samples using the calibration curve. LLOQ was determined as the lowest QC with accuracy and precision under 20%, while LOD was set at three-times the S/N ratio.
Selectivity was tested by analyzing six human blank DBS and plasma samples from different sources. Carryover was investigated by injecting a blank sample after the ana lysis of the highest ReseaRch aRticle | Bosilkovska, Déglon, Samer et al.
Bioanalysis (2014) 6(2) QC. Recovery and matrix effect were measured in quadruplicate at two different concentration levels (low and high) as shown in Table 4 . Total analyte recoveries were calculated by comparing the absolute analyte peak areas from spiked DBS (or spiked extracted plasma) to that obtained from the corresponding methanolic solutions added into an empty vial (plasma recovery) or into a vial containing a blank filter paper (DBS recovery). The quantitative evaluation of matrix effect was carried out by comparing the absolute analyte peak area of spiked methanolic solutions added into the vial containing a blank DBS with that obtained from spiked methanolic solutions added in a vial containing a blank filter paper. Similarly, matrix effect for plasma ana lysis was carried out by comparing the absolute analyte peak area of spiked methanolic solutions added into the vial containing blank extracted plasma to peak area of neat spiked methanolic solutions. Additionally, the matrix effect was evaluated qualitatively by postcolumn infusion of the reference standard solutions (c = 10 ng/ml for all substances except CAF, PAR and OH-BUP for which c = 100 ng/ml, speed = 10 µl/min), while injecting six blank DBS or plasma samples from different sources [24] .
To verify the short-term stability of the analytes on filter paper, DBS containing all the analytes at two concentration levels were prepared and stored at three different temperatures (room temperature, +4°C and -20°C). Stability was evaluated after 15 and 30 days by comparing the concentrations obtained after ana lysis at day 15, that is, day 30 with those obtained at day 0. Each measurement was performed in triplicate.
PK study
The clinical applicability of the method was evaluated in a PK study in which 10 healthy male volunteers received an oral 'cocktail' capsule containing low dose BUP (25 mg), FLB (25 mg), DEM (10 mg), OPZ (5 mg), MDZ (1 mg) and FEX (25 mg) together with a cup of coffee or coke. Capillary and venous blood samples were collected simultaneously before drug administration as well as 0.5, 1, 2, 3, 4, 6 and 8 h after intake. Capillary whole blood (10 µl) was collected on filter paper after a small finger prick (BD Microtainer, Contact-Activated Lancet, Plymouth, UK), whereas venous blood was collected into EDTA tubes (BD Vacutainer, Plymouth, UK). Plasma was obtained after centrifugation at 2500 rpm for 10 min and stored together with DBS cards at -20°C. Both DBS and plasma samples were analyzed (in duplicate) with the method described above. The clinical study was composed of four sessions in which the volunteers received the 'cocktail' capsule alone or in presence of CYP and P-gp inhibitors or inducer.
The study was conducted according to the standards of Good Clinical Practice, the Declaration of Helsinki and the Swiss regulatory requirements. The protocol was approved by the Ethics Committee of Geneva University Hospitals (ID: 12-085) and the trial was registered at ClinicalTrials.gov (ID: NCT01731067). Written informed consent was obtained from each subject prior to inclusion.
Results & discussion
Modifications and variability in drug disposition as a result of drug-drug interactions, genetic or Analyses were performed in quadruplicate (n = 4) over 3 nonconsecutive days.
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Bioanalysis (2014) 6(2) environmental factors can lead to adverse effects or therapeutic inefficacy. Since CYP are considered a major source of inter-individual variability in drug response and of potential drug-drug interactions, we decided to assess a low dose cocktail approach to phenotype these enzymes in association with P-gp using DBS with subsequent LC-MS/MS ana lysis. The objective was to optimize the entire analytical workflow (including sample collection, extraction and LC-MS ana lysis) in order to improve the throughput of the method and therefore the clinical output.
It is now well-established that filter paper offers an attractive alternative to conventional venipuncture as it provides a minimally invasive technique and an easy way to collect blood. However, filter paper is not only a sampling support; it is also a promising technique to simplify sample preparation of complex matrices before LC-MS ana lysis [24] . Indeed, the use of an appropriate organic solvent (for example MeOH Analyses were performed in quadruplicate (n = 4).
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www.future-science.com or ACN) allows the fixation of proteins and cell fragments onto the filter, while permitting the extraction of the analytes into a clear extract. Taking advantage of this, the DBS extraction can be coupled directly with LC system in an online mode. Recent papers have demonstrated the potential of this approach for drug ana lysis using dedicated DBS autosamplers [25, 26] . For the present development, we decided to use a simplified offline extraction previously described [17, 27] .
Even if this setup features additional manipulations compared with online methods, it allows the DBS extraction to be achieved using conventional LC autosampler and simplifies the LC method avoiding column switching setup. The main challenge of this work was to develop a versatile LC-MS/MS platform enabling the simultaneous quantification of six CYP probes and their respective phase I metabolites, as well as a P-gp substrate. Regarding the extraction, DBS pretreatment by means of soaking filter paper with MeOH into the vial allowed for a reliable and unbiased extraction of all tested substances. Moreover, the MeOH extraction provided sufficiently clean DBS extracts to avoid any additional clean-up step. For plasma extraction, the same strategy was applied. A generic PP was performed using ACN in order to have a nondiscriminating extraction. Despite the simplicity of both DBS and plasma extraction protocols, the selectivity of the method was confirmed since no interfering peaks were observed in blank DBS or in drug-free plasma at the retention times of the target analytes.
Within the same analytical run, generic LC conditions enabled the separation of different molecules with a wide range of polarity. The use of H 2 O without buffer or formic acid associated to a low percentage of organic solvent (i.e., 2% of ACN) during the initial step of the gradient allowed for the good focalization and separation of polar compounds (such as PAR or CAF with a LogP of -0.9 and -0.6, respectively), as well as more hydrophobic compounds on the same RP C18 column. Furthermore, the combination of a short fused-core LC column (Kinetex™, Phenomenex Inc., CA, USA) with a rapid ACN gradient delivered at a flow rate of 0.6 ml/min allowed for the rapid and efficient chromatographic separation of the analytes in less than 3 min, as illustrated in Figure 1 .
Due to the polarity switching of the TurboIonSpray interface, both positive and negative ions could be acquired simultaneously. In this way, acid compounds such as FLB and OH-FLB could be detected in negative mode and basic compounds in positive mode within the same SRM method (Table 1) .
Method performance Response function
For both plasma and DBS, the response function was linear for each analyte over the concentration ranges indicated in Table 1 . These concentration ranges were chosen based on expected plasma and/or blood concentrations for each substance after oral administration of the drug cocktail described above. The best-fit line of the calibration curve for each analyte was obtained by using a weighting factor of 1/x.
Accuracy, precision & linearity
Accuracy and precision were determined by injecting independent QC samples at four different concentration levels. Accuracy was determined as a percentage of the ratio between experimental and theoretical concentrations. Precision values were assessed by calculating the relative standard deviations for the intraday repeatability and the inter-day variability. As shown in Table 2 (DBS validation), for each compound and concentration tested the accuracy was included in the interval 92.2-111.1%, whereas both intra-day and inter-day precision were below 11%. Plasma validation data in Table 3 show that the accuracy values for every substance and concentration were in the interval 90.2-109.5%, except for the lowest OH-OPZ QC, which was slightly overestimated (115.5%) but still within the acceptable limit criteria. Precision values for all of the substances in plasma samples were lower than 15%.
For all analytes, the method was linear within the chosen concentration range with slope values between 0.922 and 1.037 for plasma, and between 0.937 and 1.030 for DBS. The coefficients of determination (R 2 ) were above 0.995 and 0.999 for plasma and DBS, respectively (data not shown).
LOD & LLOQ
LODs and LLOQs were identical for plasma and DBS since the same dilution factor was applied during the respective extraction procedures. Despite the use of a simple extraction procedure without preconcentration step for both DBS and plasma samples, the method provided sufficient sensitivity to encompass ReseaRch aRticle | Bosilkovska, Déglon, Samer et al.
Bioanalysis (2014) 6(2) the expected concentration domain of each substance. LLOQs corresponding to the lowest QC concentrations are summarized in Tables 2 & 3 , whereas estimated LODs are listed in Table 1 .
Recovery & matrix effect
Recovery and matrix effect results for both plasma and DBS are summarized in Table 4 . As shown, total recoveries for all substances at the two concentration levels were in the interval 56.6-114.8% for DBS and 67.0-102.4% for plasma. Recoveries for all substances were reproducible, which is in agreement with the good precision observed.
An issue of concern when DBS samples are used, especially when sample preparation is minimal, is the impact that hematocrit may have on the extraction efficiency of drugs. This issue was investigated in a study using similar experimental design to the present [28] . The biases observed at different hematocrit levels (from 25 to 75%) were found to be very low (between +6.3 and -5.4). These biases are within the accepted validation criteria, showing that differences in hematocrit levels would not influence the extraction efficiency of drugs.
Ion suppression or enhancement was lower than 20% for all of the substances in both DBS and plasma, indicating that there was no significant matrix effect. These results were confirmed with the postcolumn infusion test, since no variation in the MS response was observed in the elution windows of the analytes (data not shown).
Carryover
Analyte concentrations in the blank sample injected after the highest QC were lower than 20% of the LLOQ for all substances except for MDZ and OH-MDZ. For these two compounds, a carryover was observed in the blank filter injected after the highest QC sample as the signal was equal to approximately 50% . SRM chromatograms of a 10 µl DBS sample containing P-glycoprotein and cytochrome P450 probe substrates and their metabolites at the following concentrations. Caffeine 125 ng/ml; paraxanthine 125 ng/ml; OH-omeprazole 5 ng/ml; omeprazole 5 ng/ml; dextrorphan 5 ng/ml; OH-flurbiprofen 25 ng/ml; OH-bupropion 5 ng/ml; OH-midazolam 2 ng/ml; bupropion 5 ng/ml; midazolam 1 ng/ml; dextromethorphan 2 ng/ml; fexofenadine 5 ng/ml and flurbiprofen 125 ng/ml. of the signal of the LLOQ. However, no carryover was observed after the injection of the QC 3 for both MDZ and OH-MDZ. Therefore, a blank filter paper is recommended after the injection of DBS samples containing MDZ and OH-MDZ concentrations higher than 25 and 50 ng/ml, respectively. During the study, plasma and DBS concentrations in the clinical samples were found to be lower than 20 ng/ml and 5 ng/ml for MDZ and OH-MDZ, respectively.
Stability
To verify if DBS samples collected during the PK study could be shipped and stored at ambient temperature, analyte stability in DBS was investigated after storing the samples for 15 and 30 days at room temperature, +4 and -20°C. When stored for 15 days, all of the substances were stable at all temperatures (concentrations at day 15 were between 85 and 115% of the corresponding day 0 DBS samples). All substances were stable after 30-day storing at all temperatures, except for bupropion whose concentrations were 53, 71 and 81% of the corresponding day 0 sample at room temperature, +4 and -20°C, respectively. No differences in stability were observed between the high-and the low-concentrated QC samples.
The observed results indicate that DBS cards could be collected, shipped and stored at ambient temperature as long as they were analyzed in the 15 days following sampling. For longer storage periods (up to 30 days), DBS cards containing bupropion should be kept at -20°C.
PK study
The developed method was used to determine the concentrations of the probe substrates and their specific metabolites in a PK study in which ten healthy volunteers received a cocktail of the probe substances. These probes have been used and validated in different combinations in several previously published cocktail approaches at therapeutic [4, 29, 30] or subtherapeutic doses [7, 12] . The doses given to the volunteers in this study were five-to ten-times lower than usual therapeutic doses, therefore no i nteractions or side effects are expected to occur. Figure 2 illustrates representative concentration-time profiles for all substances and their metabolites, in both plasma and DBS, after the administration of cocktail drugs. Despite the low doses administered and the minimal blood volume used, the sensitivity of the method allowed the quantification of all substances over the entire sampling period (8 h) except for MDZ and OH-MDZ, which are rapidly eliminated from the organism and could only be quantified over 6 h. As it can be deduced from Figure 2 , good correlation was observed between DBS and plasma concentrations. This correlation is visually represented in ). Blood to plasma concentration ratios (R BP ) range between 0.62-1.67 for the compounds assessed with ten of the 13 compounds partitioning predominantly into plasma compared with red blood cells [31] . Some molecules such as CAF, PAR and FEX might enter the erythrocytes, but do not bind (or bind only slightly) to proteins there, yielding R BP values close to 1. Drugs such as DEM and its metabolite, which have high R BP , enter and probably bind to blood cells, although there are no previous studies that evaluate this question.
Detailed results of the PK study and the interpretation of the metabolic ratios for the assessment of CYP and P-gp activity will be published elsewhere.
Conclusion
This article describes simple extraction procedures and LC-MS/MS method for the simultaneous quantification of P-gp and CYP probe substrates, as well as their metabolites, in plasma and 10 µl DBS samples. Due to its simplicity, the present method can be easily implemented in conventional biomedical laboratories and it fulfills the expectations in terms of throughput, since all probes could be quantified within a single 6 min analytical run. The method satisfied the required international validation criteria for all of the tested compounds. Despite the simple extraction procedure (plasma PP and DBS soaking, respectively) good recoveries and no matrix effect were observed.
The validated method was successfully applied to a PK study in which healthy male volunteers received a low dose (five-to ten-times lower doses than conventional therapeutic doses) cocktail of P-gp and CYP probe substrates. Good DBS-plasma concentration correlation was observed for all of the analytes, indicating that DBS may provide an alternative sampling technique to classic venous plasma collection. DBS procedure presents several advantages in terms of sample storage and shipment (analyte stability at room temperature for at least 15 days), as well as ease of sampling and patient-friendliness, and
Bioanalysis (2014) 6(2) therefore can be preferred over plasma for CYP and P-gp phenotyping.
Future perspective
As MS coupled with LC separation continuously gain in both sensitivity and selectivity, cytochrome phenotyping could be performed with even lower probe doses and very small amounts of blood material (lower than 10 µl). The low invasiveness of the DBS sampling method represents a great advantage, which can be further used for phenotyping or PK studies in ReseaRch aRticle | Bosilkovska, Déglon, Samer et al.
Bioanalysis (2014) 6(2) more vulnerable patients, such as the pediatric or elderly population. 
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Executive summary
Experimental (LC-MS/MS ana lysis)
A single, fast (6 min) and sensitive method for the quantification of P-glycoprotein and cytochrome P450 probe substrates as well as their metabolites in DBS and/or plasma has been developed.
Results (method performance)
The LC-MS/MS method fulfilled all of the required validation criteria and was successfully applied for cytochrome and P-glycoprotein phenotyping in healthy volunteers.
Results (PK study)
The good correlation observed between plasma and DBS analyte concentrations indicates that the use of capillary DBS could be a suitable alternative to classical venous plasma ana lysis.
Conclusion
Due to the facility of sample collection and the simple extraction procedure, DBS sampling can be easily used in clinical setting for the evaluation of cytochromes and P-glycoprotein activities.
